Please login to the form below

Not currently logged in
Email:
Password:

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

National Institute for Health and Clinical Excellence (NICE)

The UK's cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) is to reconsider its decision to recommend NHS in England does not make routine use of GlaxoSmithKline's (GSK) lupus drug Benlysta (belimumab).

The agency originally turned down the drug in April this year, claiming it was too expensive for the benefits it provided, but that decision will now be referred to an expert committee after a successful appeal from GSK.

It's not the first time Benlysta has struggled for approval, having been turned down for use in Germany by Institute for Quality and Efficiency in Health Care (IQWiG), but NICE's rejection hit GSK particularly hard with its then UK general manager Simon Jose describing the original decision as “devastating” for patients with the autoimmune disease Lupus.

He said: “By denying access to belimumab, which is the first treatment specifically developed and licensed for lupus in over 50 years, UK patients are being left behind those in other countries including the US, Germany and Spain who already have access to this medicine.”

NICE puts the drug's cost at £2,308.50 for the first four weeks and then £769.50 every following four weeks, although GSK had offered a discount through a patient access scheme.

The appeals board has now upheld two points raised by GSK in its complaint about original the negative recommendation.

GSK's current UK general manager Erik van Snippenberg told Reuters: "The outcome of the appeal is a positive step. However, the restrictive nature of the NICE appraisal and appeal process remains a challenge and we continue to be concerned about our probability of achieving a successful outcome and reversing the negative determination."

The NICE appeals process is set to be overhauled soon though, following industry pressure from the Association of the British Pharmaceutical Industry (ABPI), with the Department of Health set to transfer power to appoint members of the appeal panel from NICE to the government.

7th September 2012

From: Sales, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics